Imatinib, Free Base
Imatinib, marketed by Novartis as Gleevec or Glivec, investigational name STI-571, is a tyrosine-kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive chronic myelogenous leukemia.
Cancer Research and Antivirals
|Appearance||off white solid|
Send us your enquiry for Imatinib, Free Base. We offer custom pack sizes at special prices. We aim to respond to your enquiry within 24 hours.
We value your input so if you have suggestions regarding new applications for Imatinib, Free Base email us and we will include your contribution on the website.